Wang Z, et al. - In this multicenter, randomized phase 2 trial, researchers assessed nab-paclitaxel/carboplatin (nab-PC) vs gemcitabine/carboplatin (GC) for the treatment of advanced squamous cell lung carcinoma (SCLC). The study sample consisted of 127 eligible participants. In patients with advanced SCLC, first-line treatment with nab-PC and GC offered equal responses, progression-free survival rates, and overall survival rates. Nab-PC, however, demonstrated an advantage in improving quality of life vs GC treatment.